US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump Reuters
View source →https://news.google.com/rss/articles/CBMixgFBVV95cUxNUUJ5QjBndGJPNTFwMHRqRzZVNHRqd0JpaW1oc2UxeGd0RXpYNDNWQlE2Yl9vLVBfbUxZS3ZqeG1iTnh3Um1vZXJRWU5aenBiaFlYRmRBVy00eFpYRVJFNHN0NTk2TVdWOXNfbHZKckxpRi05WDNJM2VaLWRjR1l0c3JrYkYyZEU0UFItS2NQR19Pb1cwWG1BNW43Y19mZE9EajUwZHA4RUJTOVFoOWdnbG5tT1pzdDhvVlI3MEZlcU50YWd0a2c?oc=5Hash 0x76d8395c8d3a7fb8d84e2e77406b8f6b384c21b495254815fcd1e7f6e9b51200
Connect your wallet to join the discussion.
No comments yet. Be the first to share your take.